Harvard Bioscience (NASDAQ: [[ticker:HBIO]]), a Holliston, MA-based maker of instrumentation for life sciences industries, plans to buy back some $10 million of its common stock over the next two years, the company announced yesterday. The stock is up some 6 percent this afternoon, at $4.24.
Author: Rebecca Zacks
Rebecca is Xconomy's co-founder. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University.
View all posts by Rebecca Zacks
